Drug-Induced Myoclonus: Frequency, Mechanisms and Management

CNS Drugs

Volumn 18, Issue 2, 2004, Pages 93-104

  Jiménez Jiménez, Félix Javier ^a,b,c   Puertas, Inmaculada ^a   De Toledo Heras, María ^a,b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Neuro Magister SL Co   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BISMUTH; BROMOCRIPTINE; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LEVODOPA; LITHIUM; MAPROTILINE; METHYSERGIDE; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OPIATE AGONIST; PHENYTOIN; PHYSOSTIGMINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; UNINDEXED DRUG; VALPROIC ACID;

BRAIN DISEASE; CLINICAL FEATURE; DEGENERATIVE DISEASE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; INFECTION; INSOMNIA; INVOLUNTARY MOVEMENT; MEDLINE; METABOLIC DISORDER; MUSCLE CONTRACTION; MYOCLONUS; NERVE DEGENERATION; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SLEEP DISORDER;

ANTACIDS; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; BISMUTH; DOPAMINE ANTAGONISTS; GABA AGENTS; HUMANS; MYOCLONUS; PHARMACEUTICAL PREPARATIONS; SEROTONIN AGENTS;

EID: 18544408481     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418020-00003     Document Type: Review

References (236)

1. Marsden CD, Hallet M, Fahn S. The nosology and pathophysiology of myoclonus. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworths, 1981: 196-248
2. Fahn S, Marsden CD, van Woert MH. Definition and classification of myoclonus. Adv Neurol 1986; 43: 1-5
3. Jiménez-Jiménez FJ, Luquin MR, Molina JA. Concepto y clasificación de los trastornos del movimiento. In: Jiménez- Jiménez FJ, Luquin MR, Molina JA, editors. Tratado de los trastornos del movimiento. Madrid: 1M&C, 1998: 3-17
4. Giménez-Roldán S. Neuropharmacology and treatment of myoclonus. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. 3rd ed. Baltimore (MD): Williams & Wilkins, 1998: 467-90
5. Jiménez-Jiménez FJ, García-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf 1997; 16: 180-204
6. Gordon MF. Toxin and drug-induced myoclonus. Adv Neurol 2002; 89: 49-76
7. American Academy of Neurology Quality Standards Subcommittee. Practice parameters: initial therapy of Parkinson's disease. Neurology 1993; 43: 1296-7
8. Cotzias GC, Papavasioliou PS, Gellene R. Modification of parkinsonism-chronic treatment with levodopa. N Engl J Med 1969; 280: 337-45
9. Klawans HL, Goetz C, Bergen D. Levodopa induced myoclonus. Arch Neurol 1975; 32: 331-4
10. Vardi J, Glaubman H, Rabey JM, et al. Myoclonic attacks induced by L-dopa and bromocryptin in Parkinson patients: a sleep EEG study. J Neurol 1978; 218: 35-42
11. Sandyk R. L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol 1986; 6: 194-5
12. Hirschorn KA, Greenberg HS. Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome: a case report. Clin Neuropharmacol 1988; 11: 278-81
13. Nausieda PA, Weiner WJ, Kaplan LR, et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982; 5: 183-94
14. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998; 13: 895-9
15. Luquin MR, Scipioni O, Vaamonde J, et al. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992; 7: 117-24
16. Marconi R, Lefebvre-Caparros D, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994; 9: 2-12
17. Glantz R, Weiner WJ, Goetz CG, et al. Drug-induced asterixis in Parkinson's disease. Neurology 1982; 32: 553-5
18. Neufeld MY. Periodic triphasic waves in levodopa-induced encephalopathy. Neurology 1992; 42: 444-6
19. Yoshida K, Morikawa F, Matsuura T, et al. Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPS. Jpn J Psychiatry Neurol 1993; 47: 621-5
20. Buchman AS, Bennett DA, Goetz CG. Bromocriptine-induced myoclonus. Neurology 1987; 37: 885
21. Pfeiffer RF. Amantadine-induced "vocal" myoclonus. Mov Disord 1996; 11: 104-6
22. Onofrj M, Thomas A, Iacono D, et al. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur Neurol 2001; 46: 11-6
23. Noble J, Matthew H. Acute poisoning by tricyclic antidepressants: clinical features and management of 100 patients. Clin Toxicol 1969; 2: 403-21
24. Darcourt G, Fadeuilhe A, Lavagna J, et al. Trois cas de myoclonies d'action au cors de traitements par l'imipramine et l'amitriptyline. Rev Neurol (Paris) 1970; 122: 141-2
25. Schulze B. Zur frage medikamentos induzierter cerebraler reaktionen: ein fall von myoklonischen Status under behanlung mit trycyclishen antidepressiva. Nervenarzt 1972; 43: 332-6
26. Burks JS, Walker JE, Rumack BH, et al. Tricyclic antidepressant poisoning: reversal of coma, choreoathetosis and myoclonus by physostigmine. JAMA 1974; 230: 1405-7
27. Holinger PC, Klawans HL. Reversal of tricyclic-overdosage-induced central anticholinergic syndrome by physostigmine. Am J Psychiatry 1976; 133: 1018-23
28. Lippmann S, Moskovitz R, O'Tuama L. Tricyclic induced myoclonus. Am J Psychiatry 1977; 134: 90-1
29. Lippmann S, Tucker D, Wagemaker H, et al. A second report of tricyclic-induced myoclonus [letter]. Am J Psychiatry 1977; 134: 585-6
30. Kettl P, De Paulo Jr JR. Maprotiline-induced myoclonus [letter]. J Clin Psychopharmacol 1983; 3: 264-5
31. Myers BM, Klerman GL, Hartmann E. Nocturnal cataclysms with myoclonus: a new side effect of clomipramine [letter]. Am J Psychiatry 1986; 143: 1490-1
32. Garvey MJ, Tollefson GD. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry 1987; 44: 269-72
33. Casas M, García-Ribera C, Alvarez E, et al. Myoclonic movements as a side-effect of treatment with therapeutic doses of clomipramine. Int Clin Psychopharmacol 1987; 2: 333-6
34. Devanand DP, Sackeim HA, Brown RP. Myoclonus during combined tricyclic antidepressant and lithium treatment [letter]. J Clin Psychopharmacol 1988; 8: 446-7
35. Fukuzako H, Hokazono Y, Tominaga H, et al. Jerk-locked averaging and somatosensory evoked potential in tricyclicinduced myoclonus: a case report. Jpn J Psychiatry Neurol 1989; 43: 645-9
36. Forstl H, Pohlmann-Eden B. Amplitudes of somatosensory evoked potentials reflect cortical hyperexcitability in antidepressant-induced myoclonus. Neurology 1990; 40: 924-6
37. Patterson JF. Myoclonus caused by a tricyclic antidepressant. South Med J 1990; 83: 463-5
38. Forstl H, Zagorski A, Pohlmann-Eden B. Somatosensory evoked potentials as indicators of altered cerebral excitability during psychotropic drug treatment. Biol Psychiatry 1991; 29: 397-402
39. Forstl H, Pohlmann-Eden B, Rothenberger A. Veranderungen somatosensibel evozierter potentiale bei pharmakogener myoklonie. Nervenarzt 1992; 63: 359-62
40. Lejoyeux M, Rouillon F, Ades J, et al. Neural symptoms induced by tricyclic antidepressants: phenomenology and pathophysiology. Acta Psychiatr Scand 1992; 85: 249-56
41. Masand P. Desipramine-induced oral-pharyngeal disturbances: stuttering and jaw myoclonus [letter]. J Clin Psychopharmacol 1992; 12: 444-5
42. Lejoyeux M, Ades J, Rouillon F. Myoclonies chez les patients traites par antidepresseurs tricycliques: evaluation prospective [letter]. Presse Med 1994; 23: 447
43. Black KJ, Kilzieh N. Severe imipramine-induced myoclonus in a patient with psychotic bipolar depression, catatonia, and schizencephaly. Ann Clin Psychiatry 1994; 6: 45-9
44. Brogmus KE, Lesch A. Psychopharmakainduzierte myoklonien. Psychiatr Prax 1995; 22: 77-9
45. Ackerman DL, Greenland S, Bystritsky A, et al. Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessive-compulsive disorder. J Clin Psychopharrnacol 1996; 16: 324-8
46. Vandel P, Bonin B, Leveque E, et al. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997; 7: 207-12
47. Evidente VG, Caviness JN. Focal cortical transient preceding myoclonus during lithium and tricyclic antidepressant therapy. Neurology 1999; 52: 211-3
48. Patel HC, Bruza D, Yeragani V. Myoclonus with trazodone [letter]. J Clin Psychopharmacol 1988; 8: 152
49. Feighner JP, Boyer WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222-5
50. Lauterbach EC. Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease. Mov Disord 1994; 9: 343-6
51. Lauterbach EC. Fluoxetine, buspirone, myoclonus, and dystonia [letter]. Am J Psychiatry 1995; 152: 1697
52. Bauer M. Severe myoclonus produced by fluvoxamine [letter]. J Clin Psychiatry 1995; 56: 589-90
53. Bharucha KJ, Sethi KD. Complex movement disorders induced by fluoxetine. Mov Disord 1996; 11: 324-6
54. Spigset O, Hedenmalm K, Dahl ML, et al. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997; 96: 379-84
55. Ghaziuddin N, Iqbal A, Khetarpal S. Myoclonus during prolonged treatment with sertraline in an adolescent patient. J Child Adolesc Psychopharmacol 2001; 11: 199-202
56. Darko W, Guharoy R, Rose F, et al. Myoclonus secondary to the concurrent use of trazodone and fluoxetine. Vet Hum Toxicol 2001; 43: 214-5
57. Cohen RM, Pickar D, Murphy DL. Myoclonus-associated hypomania during MAO-inhibitor treatment. Am J Psychiatry 1980; 137 (1): 105-6
58. Levy AB, Bucher P, Votolato N. Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine-tryptophan combination treatment. Can J Psychiatry 1985; 30: 434-6
59. White PD. Myoclonus and episodic delirium associated with phenelzine: a case report. J Clin Psychiatry 1987; 48: 340-1
60. Naylor MW, Grunhaus L, Cameron O. Myoclonic seizures after abrupt withdrawal from phenelzine and alprazolam. J Nerv Ment Dis 1987; 175: 111-4
61. Askenasy JJ, Yahr MD. Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated? J Neural Transm 1988; 72: 67-76
62. Morgan JL, Brown TM, Wallace IV ER. Monoamine oxidase inhibitors and sleep movements [letter]. Am J Psychiatry 1994; 151: 782
63. De Larquier A, Vial T, Brejoux G, et al. Syndrome serotoninergique lors de l'association tramadol et iproniazide [letter]. Therapie 1999; 54: 767-8
64. Lemus CZ, Lieberman JA, Johns CA. Myoclonus during treatment with clozapine and lithium: the role of serotonin. Hillside J Clin Psychiatry 1989; 11: 127-30
65. Rosen PD, Stevens R. Action myoclonus in lithium toxicity. Ann Neurol 1983; 13: 221-2
66. Julius SC, Brenner RP. Myoclonic seizures with lithium. Biol Psychiatry 1987; 22: 1184-90
67. Prettyman R. Lithium neurotoxicity at subtherapeutic serum levels [letter]. Br J Psychiatry 1994; 164: 123
68. Takahashi M, Hashimoto S, Suenaga T, et al. Creutzfeldt-Jakob like syndrome due to lithium intoxication: a case report. Rinsho Shinkeigaku 1997; 37: 338-40
69. Drouet A, Valance J. Myoclonies de repos et d'action induites par la piperazine. Rev Med Interne 1994; 15: 364-5
70. Tominaga H, Fukuzako H, Izumi K, et al. Tardive myoclonus [letter]. Lancet 1987; I: 322
71. Fukuzako H, Tominaga H, Izumi K, et al. Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients. Biol Psychiatry 1990; 27: 1116-26
72. Little JT, Jankovic J. Tardive myoclonus. Mov Disord 1987; 2: 307-11
73. Staedt J, Dewes D, Danos P, et al. Can chronic neuroleptic treatment promote sleep disturbances in elderly schizophrenic patients? Int J Geriatr Psychiatry 2000; 15 (2): 170-6
74. Berman I, Zalma A, DuRand CJ, et al. Clozapine-induced myoclonic jerks and drop attacks. J Clin Psychiatry 1992; 53: 329-30
75. Malow BA, Reese KB, Sato S, et al. Spectrum of EEG abnormalities during clozapine treatment. Electroencephalogr Clin Neurophysiol 1994; 91: 205-11
76. Meltzer HY, Ranjan R. Valproic acid treatment of clozapine-induced myoclonus. Am J Psychiatry 1994; 151: 1246-7
77. Bak TH, Bauer M, Schaub RT, et al. Myoclonus in patients treated with clozapine: a case series. J Clin Psychiatry 1995; 56: 418-22
78. Barak Y, Levine J, Weisz R. Clozapine-induced myoclonus: two case reports [letter]. J Clin Psychopharmacol 1996; 16: 339-40
79. Lu CS, Chu NS. Acute dystonic reaction with asterixis and myoclonus following metoclopramide therapy. J Neurol Neurosurg Psychiatry 1988; 51: 1002-3
80. Eisele G. Neurologic complications of metoclopramide therapy [letter]. N Y State J Med 1988; 88: 332
81. Ortí-Pareja M, Jiménez-Jiménez FJ, Vázquez A, et al. Drug-induced tardive syndromes. Parkinsonism Relat Disord 1999; 5: 59-65
82. Burns R, Thomas DW, Barron VJ. Reversible encephalopathy possibly associated with bismuth subgallate ingestion. BMJ 1974; 1: 220-3
83. Goule JP, Husson A, Fondimare A, et al. Encéphalopatie aux sels insolubles de bismuth [letter]. Nouv Presse Med 1975; 4: 1366
84. Monseu G, Struelens M, Roland M. Bismuth encephalopathy. Acta Neurol Belg 1976; 76: 301-8
85. Buge A, Rancurel G, Dechy H. Encéphalopathies myocloniques bismuthiques: formes évolutives, complications tardives, durables ou définitives: a propos de 41 cases. Rev Neurol (Paris) 1977; 133: 401-15
86. Supino-Viterbo V, Sicard C, Risvegliato M, et al. Toxic encephalopathy due to ingestion of bismuth salts: clinical and EEG studies in 45 patients. J Neurol Neurosurg Psychiatry 1977; 40: 748-52
87. Cervello MA, Alfaro A, Antolín MA, et al. Encefalopatía mioclónica bismútica: a propósito de dos nuevas observaciones clínicas. Med Clin (Barc) 1982; 79: 137-40
88. Nogué S, Más A, Parés A, et al. Encefalopatí a mioclónica y convulsiva por bismuto: utilidad del tratamiento con dimer-caprol. Med Clin (Barc) 1985; 84: 530-2
89. Sanz Gallen P, Nogue Xarau S. Intoxicación por sales de bismuto. Med Clin (Barc) 1985; 84: 538-41
90. Vidailhet M, Le TH, Wechsler B, et al. L'encephalopathie au bismuth n'a pas disparu. [letter]. Presse Med 1987; 16: 1054
91. Gómez-Jiménez J, Alvarez J, Boada-Rovira M, et al. Encelafopatía mioclónica por bismuto [letter]. Rev Clin Esp 1989; 184: 212
92. Molina JA, Calandre L, Bermejo F. Myoclonic encephalopathy due to bismuth salts: treatment with dimercaprol and analysis of CSF transmitters. Acta Neurol Scand 1989; 79: 200-3
93. Molina JA, Calandre L, Bermejo F, et al. Encefalopatía mioclónica por sales de bismuto: eficacia del tratamiento con dimercaprol. Med Clin Barc 1989; 93: 20-2
94. Mendelowitz PC, Hoffman RS, Weber S. Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy. Ann Intern Med 1990; 112: 140-1
95. Jungreis AC, Schaumburg HH. Encephalopathy from abuse of bismuth subsalicylate (Pepto-Bismol). Neurology 1993; 43: 1265
96. Gordon MF, Abrams RI, Rubin DB, et al. Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus. Mov Disord 1995; 10: 220-2
97. Bouchon JP, Cottin Bouchon D. Une mamie pas si folle que cela...intoxication au bismuth. Rev Med Interne 2001; 22 Suppl. 2: 245s-6s
98. Eeg-Oleson O, Lindskog U. Acute intoxication with valproate [letter]. Lancet 1982; I: 1306
99. Aguglia U, Gambardella A, Zappia M, et al. Negative myoclonus during valproate-related stupor: neurophysiological evidence of a cortical non-epileptic origin. Electroencephalogr Clin Neurophysiol 1995; 94: 103-8
100. Wendland KL. Myoklonien nach gaben von carbamazepin. Nervenarzt 1968; 39: 231-3
101. Aguglia U, Zappia M, Quattrone A. Carbamazepine-induced nonepileptic myoclonus in a child with benign epilepsy. Epilepsia 1987; 28: 515-8
102. Dhuna A, Pascual-Leone A, Talwar D. Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine. Epilepsia 1991; 32: 275-8
103. Go T. Carbamazepine-induced involuntary movements in a girl with localization-related epilepsy. No To Hattatsu 1999; 31: 366-9
104. Gottwald W. Transitorisches abheilen von psoriasisief-floreszenzen wherend hydantoinvergiftung mit seltener zentralnervoser symptomatik. Dermatol Wochenschr 1968; 154: 241-51
105. Chi WM, Chua KS, Kong KH. Phenytoin-induced asterixis: uncommon or under-diagnosed? Brain Inj 2000; 14: 847-50
106. Reeves AL, So EL, Sharbrough FW, et al. Movement disorders associated with the use of gabapentin. Epilepsia 1996; 37: 988-90
107. Janzsky J, Rasonyi G, Halasz I, et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level: report of two cases. Clin Neuropharmacol 2000; 23: 86-9
108. Glavina MJ, Robertshaw R. Myoclonic spasms following intrathecal morphine. Anaesthesia 1988; 43: 389-90
109. Potter JM, Reid DB, Shaw RJ, et al. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ 1989; 299: 150-3
110. Jayawardena B, Hill DJ. Myoclonic spasms after epidural diamorphine infusion. Anaesthesia 1991; 46: 473-4
111. De Conno F, Caraceni A, Martini C, et al. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47: 337-9
112. Franco ML, Berro MJ, Sáez JM, et al. Mioclonías de miembros inferiores como complicación de la morfina espinal. Rev Esp Anestesiol Reanim 1992; 39: 192-3
113. Sjogren P, Jonsson T, Jensen NH, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55: 93-7
114. Cartwright PD, Hesse C, Jackson AO. Myoclonic spasms following intrathecal diamorphine. J Pain Symptom Manage 1993; 8: 492-5
115. De-Armendi AJ, Fahey M, Ryan JF. Morphine-induced myoclonic movements in a pediatric pain patient. Anesth Analg 1993; 77: 191-2
116. Bowdle TA, Rooke GA. Postoperative myoclonus and rigidity after anesthesia with opioids. Anesth Analg 1994; 78: 783-6
117. Kloke M, Bingel U, Seeber S. Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking. Support Care Cancer 1994; 2: 249-52
118. Jacobsen LS, Olsen AK, Sjogren P, et al. Morphine-induced hyperalgesia, allodynia and myoclonus: new side-effects of morphine? Ugeskr Laeger 1995; 157: 3307-10
119. Sjogren P, Thunedborg LP, Christrup L, et al. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthersiol Scand 1998; 42: 1070-5
120. Twycross R. Opioid-induced myoclonus and seizures. J Pain Symptom Manage 1998; 15: 143-4
121. Petzinger G, Mayer SA, Przedborski S. Fentanyl-induced dyskinesias [letter]. Mov Disord 1995; 10: 679-80
122. Adair JC, el-Nachef A, Cutler P. Fentanyl neurotoxicity [letter]. Ann Emerg Med 1996; 27: 791-2
123. Bruera E, Pereira J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain 1997; 69: 199-201
124. Stueremburg HJ, Claassen J, Eggers C, et al. Acute adverse reaction to fentanyl in a 55 year old man. J Neurol Neurosurg Psychiatry 2000; 69: 281-2
125. Han PK, Arnold R, Bond G, et al. Myoclonus secondary to withdrawal from transdermal fentanyl: case report and literature review. J Pain Symptom Manage 2002; 23: 66-72
126. Mancini I, Lossignol DA, Body JJ. Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 2000; 12: 308-13
127. Sharhill N, Davis MP, Walsh D, et al. Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Care 2001; 18: 51-3
128. Adair JC, Gilmore RL. Meperidine neurotoxicity after organ transplantation. J Toxicol Clin Toxicol 1994; 32: 325-8
129. Reutens DC, Stewart-Wynne EG. Norpethidine induced myoclonus in a patient with renal failure. J Neurol Neurosurg Psychiatry 1989; 52: 1450-1
130. Lauterbach EC. Hiccup and apparent myoclonus after hydrocodone: review of the opiate-related hiccup and myoclonus literature. Clin Neuropharmacol 1999; 22: 87-92
131. Ammenti A, Reither B, Muller-Wiefel DE. Chlorambucil neurotoxicity: report of two cases. Helv Paediatr Acta 1980; 35: 281-7
132. Byrne Jr TN, Moseley III TAE, Finer MA. Myoclonic seizures following chlorambucil overdose. Ann Neurol 1981; 9: 191-4
133. LaDelfa I, Bayer N, Myers R, et al. Chlorambucil-induced myoclonic seizures in an adult. J Clin Oncol 1985; 3: 1691-2
134. Willye AR, Bayliff CD, Kovacs MJ. Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother 1997; 31: 171-4
135. Martín M, Díaz-Rubio E, Casado A, et al. Prednimustine-induced myoclonus: a report of three cases. Acta Oncol 1994; 33: 81-2
136. Monnerat C, Gander M, Leyvraz S. A rare case of prednimustine-induced myoclonus [letter]. J Natl Cancer Inst 1997; 89: 173-4
137. Ezpeleta-Echavarri D, Muñoz-Blanco JL, Díaz-Otero F, et al. Mioclonías inducidas por prednimustina [letter]. Neurologia 1998; 13: 154-5
138. Meloni G, Raucci U, Pinto RM, et al. Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study. Ann Oncol 1992; 3: 145-8
139. Wengs WJ, Talwar D, Bernard J. Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol 1993; 50: 1104-5
140. New PS, Wells CE. Cerebral toxicity associated with massive intravenous penicillin therapy. Neurology 1965; 15: 1052-8
141. Bllomer HA, Barton LJ, Maddock Jr RK. Penicillin-induced encephalopathy in uremic patients. JAMA 1967; 200: 121-3
142. Lerner PI, Smith H, Weinstein L. Penicillin neurotoxicity. Ann N Y Acad Sci 1967; 145: 310-8
143. Cohill DF, Pezzi PJ, Greenberg SR, et al. Central nervous system toxicity secondary to massive dosis of penicillin 'G' in the treatment of overwhelming infections. Am J Med Sci 1967; 254: 692-4
144. Conway N, Beck E, Somerville J. Penicillin encephalopathy. Postgrad Med J 1968; 44: 891-7
145. Kurtzman NA, Rogets PW, Harter HR. Neurotoxic reaction to penicillin and carbenicillin. JAMA 1970; 214: 1320-1
146. Fossieck Jr B, Parker RH. Neurotoxicity during intravenous infusion of penicillin: a review. J Clin Pharmacol 1974; 14: 504-12
147. Sackellares JC, Smith DB. Myoclonus with electrocerebral silence in a patient receiving penicillin. Arch Neurol 1979; 36: 857-8
148. Kallay MC, Tabechian H, Riley GR, et al. Neurotoxicity due to ticarcillin in patient with renal failure [letter]. Lancet 1979; I: 608-9
149. Slaker RA, Danielson B. Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction. Pharmacotherapy 1991; 11: 351-2
150. Klion AD, Kallsen J, Cowl CT, et al. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med 1994; 154: 586-9
151. Uchihara T, Tsukagoshi H. Myoclonic activity associated with cefmetazole, with a review of neurotoxicity of cephalosporins. Clin Neurol Neurosurg 1988; 90: 369-71
152. Herishanu YO, Zlotnik M, Mostoslavsky M, et al. Cefuroxime-induced encephalopathy. Neurology 1998; 50: 1873-5
153. Jallon P, Fankhauser L, Du Pasquier R, et al. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30: 383-6
154. Calandra GB, Brown KR, Grad LC, et al. Review of adverse experiences and tolerability in the first 2516 patients treated with imipenem/cilastatin. Am J Med 1985; 78 (6A): 73-8
155. Frucht S, Eidelberg D. Imipenem-induced myoclonus. Mov Disord 1997; 12: 621-2
156. Park-Matsumoto YC, Tazawa T. Piperacillin-induced encephalopathy [letter]. J Neurol Sci 1996; 140: 141-2
157. Durand JM, Telle H, Quiles N, et al. Syndrome confusionnel, myoclonies et traitement par la pefloxacine. Ann Med Interne (Paris) 1993; 144: 495-6
158. Yashuda H, Yoshida A, Masuta Y, et al. Levofloxacin-induced neurological adverse effects such as convulsion, involuntary movement (tremor, myoclonus and chorea like), visual hallucination in two elderly patients. Nippon Ronen Igakkai Zasshi 1999; 36: 213-7
159. Neau JP, Rogez R, Boissonnot L, et al. Accidents neurologiques de la piperazine. Acta Neurol Belg 1984; 84: 26-34
160. Yagi S, Moriya O, Nakajima M, et al. A case of tuberculous pleurisy associated with myoclonus and Quincke's edema due to isoniazid and isoniazid sodium methanesulfonate. Kekkaku 1989; 64: 407-12
161. Schaumburg HH. Acyclovir: In: Spencer PS, Schaumburg HH, Ludolph AC, editors. Experimental and clinical neurotoxicology. New York: Oxford University Press, 2000: 135-6
162. Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone [letter]. Psychosomatics 1992; 33: 235-6
163. Ritchie EC, Bridenbaugh RH, Jabbari B. Acute generalized myoclonus following buspirone administration. J Clin Psychiatry 1988; 49: 242-3
164. Lee DS, Wong HA, Knoppert DC. Myoclonus associated with lorazepam therapy in very-low-birth-weight infants. Biol Neonate 1994; 66: 311-5
165. Magny JF, d'Allest AM, Nedelcoux H, et al. Midazolam and myoclonus in neonate. Eur J Pediatr 1994; 153: 389-90
166. Roth BA, Vinson DR, Kim S. Carisoprodol-induced myoclonic encephalopathy. J Toxicol Clin Toxicol 1998; 36: 609-12
167. Moore C. Oxazepam withdrawal syndrome [letter]. Med J Aust 1982; 2: 220
168. Melcor CS, Jain VK. Diazepam withdrawal syndrome: its prolonged and changing nature. CMAJ 1982; 127: 1093-6
169. Madigand M, Dien J, Pavin G, et al. Encephalopathie myoclonique probablement imputable a la propafenone [letter]. Presse Med 1988; 17: 538
170. Jeandel C, Bannwarth B, Trechot P, et al. Encephalopathie myoclonique a la propafenone. Therapie 1990; 45: 161-2
171. Chua TP, Farrell T, Lipkin DP. Myoclonus associated with propafenone [letter]. BMJ 1994; 308: 113
172. Ghika J, Goy JJ, Naegeli C, et al. Acute reversible ataxomyoclonic encephalopathy with flecainide therapy. Schweiz Arch Neurol Psychiatr 1994; 145: 4-6
173. Jeret JS, Somasundaram M, Asaikar S. Diltiazem-induced myoclonus. N Y State J Med 1992; 92: 447-8
174. Pedro-Botet ML, Bonal J, Caralps A. Nifedipine and myoclonic disorders [letter]. Nephron 1989; 51: 281
175. Lucas C, Soetaert G, Leys D, et al. Myoclonies au cours d'un traitement par buflomedil. Acta Clin Belg 1989; 44: 360-1
176. Fukuda T. Veratramine-induced myoclonus. Seishin Shinkeigaku Zasshi 1990; 92: 865-9
177. Bouly A, Nathan N, Feiss P. Propofol in myotonic dystrophy [letter]. Anaesthesia 1991; 46: 705
178. Hughes NJ, Lyons JB. Prolonged myoclonus and meningism following propofol. Can J Anaesth 1995; 42: 744-6
179. Gooding JM, Corssen G. Etomidate: an ultrashort-acting nonbarbiturate agent to anesthesia induction. Anesth Analg 1976; 55: 286-9
180. Kay B. Some experience of the use of etomidate in children. Acta Anaesthesiol Belg 1976; 27 Suppl.: 86-92
181. Dubois DJ, Basternier GJ, Genicot C, et al. A comparative study of etomidate and methohexital as induction agents for analgesia anesthesia. Acta Anaesthesiol Belg 1976; 27 Suppl.: 187-95
182. Fameno CE, Odughesan CO. Further experience with etomidate. Can Anaesth Soc J 1978; 25: 130-2
183. Ng AT. Prolonged myoclonic contractions after enflurane anesthesia. Can Anaesth Soc J 1980; 27: 502-3
184. Hudson R, Ethans CT. Alfathesin and enflurane: synergistic central nervous system excitation? Can Anaesth Soc J 1981; 28: 55-6
185. Kurtz D, Tempe JD, Weber M, et al. Electroclinical aspects of acute intoxication with chloralose [letter]. Electroencephalogr Clin Neurophysiol 1968; 24: 489
186. Cornette M, Franck G. Clinical and EEG features of acute drug intoxication with chloralose in eleven recent cases [letter]. Electroencephalogr Clin Neurophysiol 1981; 30: 374
187. Fox EJ, Villanueva R, Scutta HS. Myoclonus following spinal anesthesia. Neurology 1979; 29: 379-80
188. Schipior PG. An unusual case of antihistamine intoxication. J Pediatr 1967; 71: 589-91
189. Jacquesson M, Saudeau D, Pantin B, et al. Myoclonies imputables a une association de triprolidine, de pseudoephedrine et de paracetamol. Nouv Presse Med 1982; 11: 2298-9
190. Sica DA, Comstock TJ. Pseudoephedrine accumulation in renal failure. Am J Med Sci 1989; 298: 261-3
191. Mayeux R, Albert M, Jenike M. Physostigmine-induced myoclonus in Alzheimer's disease. Neurology 1987; 37: 345-6
192. Korthals JK, Gieron-Korthals MA. Eosinophilia-myalgia syndrome with myoclonic jerks. J Fla Med Assoc 1990; 77: 1031-3
193. Baloh RW, Dietz J, Spooner JW. Myoclonus and ocular oscillations induced by L-tryptophan. Ann Neurol 1982; 11: 95-7
194. Bandelot JB, Mihout B. Encephalopathie myoclonique imputable au diclofenac [letter]. Nouv Presse Med 1978; 7: 1406
195. Alcalay M, Thomar P, Reboux JF, et al. Myoclonies au curs d'un traitement par le diclofenac. Sem Hop 1979; 55: 679-80
196. Ozer EA, Turker M, Bakiler AR, et al. Involuntary movements in infantile cobalamin deficiency appearing after treatment. Pediatr Neurol 2001; 25: 81-3
197. Van Sweden B, Kamphuisen HA. Cimetidine neurotoxicity. Eur Neurol 1984; 23: 300-5
198. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13
199. Chechani V. Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. Crit Care Med 2002; 30: 473-6
200. Dike GL. Triphasic waves in serotonin syndrome [letter]. J Neurol Neurosurg Psychiatry 1997; 62: 200
201. Lejoyeux M, Rouillon F, Ades J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine. Acta Psychiatr Scand 1993; 88: 369-71
202. Weiner AL, Tilden Jr FF, McKay Jr CA. Serotonin syndrome: case report and review of the literature. Conn Med 1997; 61 (11): 717-21
203. Jahr JS, Pisto JD, Gitlin MC, et al. The serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg 1994; 79: 189-91
204. Skop BP, Finklestein JA, Mareth TR, et al. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 1994; 12: 642-4
205. Ghika-Schmid F, Ghika J, Vuadens P, et al. Acute reversible myoclonic encephalopathy associated with fluoxetine therapy. Mov Disord 1997; 12: 622-3
206. Bhatara VS, Magnus RD, Paul KL, et al. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998; 32: 432-6
207. Cavallazzi LO, Grezesiuk AK. Sindrome serotoninerguca associado ao uso de paroxetine: relate de un caso. Arq Neuropsiquiatr 1999; 57: 886-9
208. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome: presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79: 201-9
209. Brendel DH, Bodkin JA, Yang JM. Massive sertraline overdose. Ann Emerg Med 2000; 36: 524-6
210. Manos GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann Pharmacother 2000; 34: 871-4
211. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995; 45: 219-23
212. Loza B. A case of serotonin syndrome. Psychiatr Pol 1995; 29: 529-38
213. Nisijima K, Shimizu M, Abe T, et al. A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. Int J Psychopharmacol 1996; 11: 289-90
214. Gillman PK. Possible serotonin syndrome with moclobemide and pethidine [letter]. Med J Aust 1995; 162: 554
215. Eisele Jr JH, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992; 51: 231-2
216. Holdsworth MT, Adams VR, Chavez CM, et al. Continuous midazolam infusion for the management of morphine-induced myoclonus. Ann Pharmacother 1995; 29: 25-9
217. Mercadente S. Dantrolene treatment of opioid-induced myoclonus. Anesth Analg 1995; 81: 1307-8
218. Kolesnikov Y, Jain S, Wilson R, et al. Blockade of morphine-induced hindlimb myoclonic seizures in mice by ketamine. Pharmacol Biochem Behav 1997; 56: 423-5
219. Lothman EW. Intravenous penicillin and myoclonus [letter]. Arch Neurol 1980; 37: 531
220. Munar-Ques M, Mulet Gutiérrez M, Cerda-Bibiloni JJ, et al. Encefalopatía penicilínica: estudio de 2 casos. Med Clin (Barc) 1983; 81: 632-3
221. Klawans HL, Carvey PM, Tanner CM, et al. Drug-induced myoclonus. Adv Neurol 1986; 43: 251-64
222. Weiner WJ, Carvey PM, Nausieda PA, et al. Dopaminergic antagonism of L-5-hydroxytryptophan-induced myoclonic jumping behavior. Neurology 1979; 29: 1622-5
223. Menon MK, Kodama CK, Kling AS, et al. An in vivo pharmacological method for the quantitative evaluation of the central effects of alpha-1-adrenoceptor agonists and antagonists. Neuropharmacology 1986; 25: 503-8
224. Lhermitte F, Peterfalvi M, Marteau R, et al. Analyse pharmacologique d'un cas de myoclonies d'intention et d'action post-anoxiques. Rev Neurol (Paris) 1971; 124: 21-31
225. Giménez-Roldán S, Mateo D, Muradas V, et al. Clinical, biochemical, and pharmacological observations in patient with postasphyxic myoclonus: association with serotonin hyperactivity. Clin Neuropharmacol 1988; 11: 151-60
226. Van Woert MH, Magnussen I, Rosenbaum D, et al. Fluoxetine in the treatment of action myoclonus. Clin Neuropharmacol 1983; 6: 49-54
227. Klawans HL, Goetz CG, Weiner WJ. 5-hydroxytryptophan-induced myoclonus in guinea pigs and the possible role of serotonin in infantile spasms. Neurology 1973; 23: 1234-40
228. Chadwick D, Hallett M, Jenner P, et al. 5-hydroxytryptophan-induced myoclonus in guinea pigs: a physiological and pharmacological investigations. J Neurol Sci 1978; 35 (1): 157-65
229. Volkman PH, Lorenz SA, Kindel GH, et al. L-5-hydroxytryptophan-induced myoclonus in guinea pigs: a model for the study of central serotonin-dopamine interaction. Neuropharmacology 1978; 17: 947-55
230. Luscombe G, Jenner P, Marsden CD. Myoclonus in guinea pigs is induced by indole-containing but not piperazine-containing 5-HT agonists. Life Sci 1982; 30: 1487-94
231. Luscombe G, Jenner P, Marsden CD. Alterations in brain 5HT and
232. 2 receptor interaction. Brain Res Bull 1993; 30: 687-9
233. Pranzatelli MR, Tailor PT, Razi P. Brainstem serotonin receptors in the guinea pig: implications for myoclonus. Neuropharmacology 1993; 32: 209-15
234. 1/2 receptor subtypes. Eur J Pharmacol 1998; 347: 51-6
235. Valin A, Cepeda C, Rey E, et al. Opposite effects of lorazepam on two kinds of myoclonus in the photosensitive Papio papio. Electroencephalogr Clin Neurophysiol 1981; 52: 647-51
236. Cepeda C, Valin A, Calderazzo L, et al. Myoclonies induites par certaines benzodiazepines chez le Papio papio: comparaison avec les myoclonies induites par la stimulation lumineuse intermittente. Rev Electroencephalogr Neurophysiol Clin 1982; 12: 32-7